Trial of Docetaxel and Cisplatin with Radiotherapy for Oesophageal Cancer
Author Information
Author(s): Day F L, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg J R, Rischin D, McKendick J, Milner A D, Di Iulio J, Matera A, Michael M
Primary Institution: Peter MacCallum Cancer Centre
Hypothesis
What is the maximum tolerated dose of a novel weekly docetaxel and cisplatin regimen concurrent with radical radiotherapy in locally advanced oesophageal cancer?
Conclusion
Cisplatin and docetaxel each 30 mg/m² per week concurrent with 50 Gy radiotherapy is recommended for use in phase II clinical trials in oesophageal cancer.
Supporting Evidence
- 24 patients were enrolled in the trial.
- Two dose-limiting toxicities were observed: grade 3 fever and grade 3 nausea.
- The overall response rate to treatment was 50%.
Takeaway
Doctors tested a new treatment for a type of throat cancer and found a safe dose that can help patients.
Methodology
Patients with unresectable, non-metastatic locally advanced oesophageal cancer received weekly docetaxel and cisplatin along with radiotherapy, with dose levels adjusted based on toxicity.
Limitations
The study was not powered to demonstrate improvements in cancer outcomes and had a small sample size.
Participant Demographics
Median age was 58 years, with 92% male and a mix of squamous cell carcinoma and adenocarcinoma histologies.
Statistical Information
Confidence Interval
95% CI 0.75–6.81 years for progression-free survival
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website